
OSTX Stock Forecast & Price Target
OSTX Analyst Ratings
Bulls say
OS Therapies Inc. has demonstrated a strong two-year overall survival rate of 75% for its treatment OST-HER2 in patients with fully resected pulmonary metastatic osteosarcoma, significantly outperforming the historical control rate of 40%. The upcoming biomarker correlation dataset anticipated in November 2025 is likely to bolster the regulatory approval pathway for OST-HER2, with both the UKMHRA and FDA showing responsive interest in utilizing historical control data for the treatment's evaluation. Furthermore, the favorable feedback from key regulatory agencies regarding the potential for conditional approval based on overall survival metrics and biomarker data enhances the positive investment thesis for OS Therapies.
Bears say
The financial analysis indicates that OS Therapies Inc. faces significant challenges due to its clinical-stage status, which often entails high burn rates and the necessity for substantial funding to progress drug development. Additionally, the absence of commercialized products and reliance on external capital presents a risk, as future funding will be critical to sustain operations and drive clinical trials forward. Furthermore, the competitive landscape of oncology treatments, coupled with potential regulatory hurdles, raises concerns about the company's ability to successfully bring its therapies to market within a favorable timeframe.
This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.
OSTX Analyst Forecast & Price Prediction
Start investing in OSTX
Order type
Buy in
Order amount
Est. shares
0 shares